Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections
Status:
Completed
Trial end date:
1999-06-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Evaluate whether thalidomide modulates toxic host inflammatory responses in
patients receiving antitubercular therapy.
II. Evaluate whether thalidomide modifies tumor necrosis factor-mediated toxic symptoms of
HIV and mycobacterial infections, and limits progression of HIV immunodeficiency.
III. Evaluate whether thalidomide stimulates immunity in patients with HIV and/or
mycobacterial infections.
Phase:
Phase 2
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) Rockefeller University